EYE-GO A/SAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet EYE-GO LABS ApS.
Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 11.959.000 | 1.201.436 | 760.395 | 6.429.715 | 228.233 | 9.048.168 | 3.704.241 | 4.345.757 | 3.078.789 |
| Omsætningsaktiver i alt | — | — | — | 8.958.023 | 2.854.091 | 11.075.239 | 7.701.744 | 6.524.544 | 7.332.841 |
| Anlægsaktiver i alt | 66.000 | 72.760 | 58.162 | 58.162 | 58.162 | 9.578.729 | 19.377.364 | 25.111.976 | 36.394.750 |
| Aktiver i alt | 13.078.000 | 6.598.056 | 5.139.628 | 9.016.185 | 2.912.253 | 20.653.968 | 27.079.108 | 31.636.520 | 43.727.591 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 447.000 | 1.011.154 | 480.114 | 1.106.034 | 496.479 | 10.401.219 | 1.633.808 | 690.293 | 13.448.743 |
| Langfristede gældsforpligtelser | — | — | 28.815 | 5.104.900 | 5.264.818 | 5.546.391 | 6.021.564 | 6.558.786 | 5.436.223 |
| Gældsforpligtelser i alt | 447.000 | 1.011.154 | 508.929 | 6.210.934 | 5.761.297 | 15.947.610 | 7.655.372 | 7.249.079 | 18.884.966 |
| Selskabskapital | 1.085.000 | 1.084.838 | 2.167.870 | 2.216.045 | 2.216.045 | 2.381.242 | 7.314.501 | 14.314.501 | 14.314.501 |
| Overført resultat | -13.641.000 | -20.684.222 | 2.462.829 | 589.206 | -5.065.089 | -3.489.572 | -1.715.129 | -8.630.589 | -19.376.893 |
| Årets resultat | -10.903.000 | -7.043.685 | -3.956.201 | -3.492.115 | -5.654.295 | -644.647 | -1.088.011 | -2.036.296 | -1.578.999 |
| Egenkapital i alt | 12.631.000 | 5.586.902 | 4.630.699 | 2.805.251 | -2.849.044 | 4.706.358 | 19.423.736 | 24.387.441 | 22.808.442 |
| Resultatopgørelse | |||||||||
| Bruttofortjeneste | -5.303.000 | -7.855.430 | -3.028.217 | -3.187.784 | -4.487.992 | -729.160 | -1.853.676 | -1.090.127 | -1.864.497 |
| Resultat af primær drift | -10.792.000 | -10.803.285 | -5.098.614 | -4.420.975 | -6.952.571 | -2.005.735 | -3.250.432 | -2.528.541 | -3.304.544 |
| EBITDA | -6.264.000 | -10.789.273 | -5.084.016 | -4.420.975 | — | -1.720.670 | -2.780.251 | -2.058.360 | -2.834.363 |
| Resultat før skat | -10.903.000 | -10.815.847 | -5.068.037 | -4.469.431 | -7.201.167 | -2.284.687 | -3.347.150 | -2.747.319 | -2.795.618 |
| Årets resultat | -10.903.000 | -7.043.685 | -3.956.201 | -3.492.115 | -5.654.295 | -644.647 | -1.088.011 | -2.036.296 | -1.578.999 |
| Personaleomkostninger | 961.000 | 2.933.843 | 2.055.799 | 1.233.191 | 2.464.579 | 991.510 | 926.575 | 968.233 | 969.866 |
| Af- og nedskrivninger | 4.528.000 | 14.012 | 14.598 | 0 | — | 285.065 | 470.181 | 470.181 | 470.181 |
| Andre nøgletal | |||||||||
| Ansatte | — | — | 3 | 1 | 3 | 5 | 6 | 6 | 5 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025EYE-GO develops disruptive eye care technology that improves the quality of life of people around the world suffering from severe and chronic eye conditions. Revolutionizing the exiting eye drop bottle market, the MistGo® product is a novel ocular drug delivery system that is the first viable and truly replacement of the eye drop bottle.MistGo® works by micro-dosing a thin mist into the eye and is part of the next generation delivery systems capable of administering micro-doses for preservative-free liquids. MistGo® is the only system effectively removing all the well-known negative effects and barriers from eye-drop bottles. Patients receive the optimal dose with precise installation every time, minimizing systemic exposure. The product has an eye guide which ensures accurate delivery of the medication into the eye and at the same time reduces risk of contamination by ensuring that no parts of the product touch the ocular surface. The technology behind transforms the 6-8 µL into a precisely targeted mist and is patented in the USA, Europe, Japan, and pending patents in China.In 2025 we have fine-tuned the MistGo® product and customers have made trials with specific real-life formulations. These tests have confirmed that MistGo® has a wide performance window regarding viscosity, and the system does not clog even with sticky formulations.In 2025 we received a convertible loan from a strategic investor (Topcon Healthcare Inc.), which is an international world-leading ophthalmol
The income statement for 2025 shows a loss of DKK 1,578,999 against a loss of DKK 2,036,296 last year, and the balance sheet at 31 December 2025 shows equity of DKK 22,808,442. The result is as expected, and the company follows the plans.The Company has made significant investments in recent years, resulting in negative cash flows, and the continued operations and development activities are dependent on obtaining additional funding. A material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern due to its liquidity position and the need to secure further financing. Reference is made to note 2 in the financial statements regarding the going concern uncertainties.
Uddrag af ledelsesberetningen i den seneste årsrapport.